Dihydrostreptomycin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Dihydrostreptomycin
- Accession Number
- DB11512
- Description
Dihydrostreptomycin is an antibiotic.
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved, Withdrawn
- Structure
Structure for Dihydrostreptomycin (DB11512)
- Weight
- Average: 583.596
Monoisotopic: 583.281319788 - Chemical Formula
- C21H41N7O12
- Synonyms
- DHMS
- Dihidroestreptomicina
- Dihydrostreptomycin
- Dihydrostreptomycine
- Dihydrostreptomycinum
- DST
- N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
- N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
- N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Dihydrostreptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Dihydrostreptomycin. Acemetacin The risk or severity of nephrotoxicity can be increased when Dihydrostreptomycin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Dihydrostreptomycin is combined with Acenocoumarol. Acetaminophen Dihydrostreptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetylcholine The therapeutic efficacy of Acetylcholine can be decreased when used in combination with Dihydrostreptomycin. Acetyldigitoxin The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Acetyldigitoxin. Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Dihydrostreptomycin. Aclidinium Dihydrostreptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Dihydrostreptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Dihydrostreptomycin sulfate T7D4876IUE 5490-27-7 CZWJCQXZZJHHRH-YCRXJPFRSA-N - International/Other Brands
- Panstreptin
Categories
- ATC Codes
- S01AA15 — Dihydrostreptomycin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminocyclitol glycosides
- Alternative Parents
- O-glycosyl compounds / Cyclohexanols / Oxanes / Monosaccharides / Cyclitols and derivatives / Tetrahydrofurans / Tertiary alcohols / Guanidines / 1,2-aminoalcohols / Propargyl-type 1,3-dipolar organic compounds show 8 more
- Substituents
- 1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Amino cyclitol glycoside / Carboximidamide / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol show 20 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- streptomycins (CHEBI:38291)
Chemical Identifiers
- UNII
- P2I6R8W6UA
- CAS number
- 128-46-1
- InChI Key
- ASXBYYWOLISCLQ-HZYVHMACSA-N
- InChI
- InChI=1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
- IUPAC Name
- N-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine
- SMILES
- CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO
References
- General References
- CURCI G: [Dihydrostreptomycin]. Arch Tisiol Mal Appar Respir. 1951 Mar;6(3):Varia, 104-6. [PubMed:14830485]
- Midtvedt T: [Dihydrostreptomycin]. Tidsskr Nor Laegeforen. 1970 Apr 15;90(8):791. [PubMed:4194808]
- BARTZ QR, CONTROULIS J, et al.: Dihydrostreptomycin. J Am Chem Soc. 1946 Nov;68(11):2163-6. [PubMed:21002218]
- HARRISON WH: Dihydrostreptomycin deafness. Antibiot Annu. 1959-1960;7:549-51. [PubMed:14400056]
- SHAMBAUGH GE Jr, DERLACKI EL, HARRISON WH, HOUSE H, HOUSE W, HILDYARD V, SCHUKNECHT H, SHEA JJ: Dihydrostreptomycin deafness. J Am Med Assoc. 1959 Aug 1;170(14):1657-60. [PubMed:13672753]
- MAHADY SC, ARMSTRONG FL, MONROE J: Purified dihydrostreptomycin. Am Rev Tuberc. 1956 May;73(5):776-8. [PubMed:13313964]
- AGOPSOWICZ G, BEKIERKUNST A, HOCHBERGER B, JEDRZEJEWSKA A, KOSSOWSKI S: [Dihydrostreptomycin and dihydrostreptomycin-penicillin therapy of ozena]. Arch Immunol Ther Exp (Warsz). 1955;3:239-47. [PubMed:13395829]
- LEES JK, MARKLE DM: Dihydrostreptomycin and deafness. N Y State J Med. 1953 Dec 15;53(24):2997-9. [PubMed:13111505]
- Authors unspecified: [Dihydrostreptomycin in pulmonary tuberculosis]. Dia Med. 1951 Sep 24;23(64):2861; passim. [PubMed:14879647]
- SHANE SJ, LAURIE JH: Neurotoxicity of dihydrostreptomycin. Can Med Assoc J. 1950 Sep;63(3):277-9. [PubMed:15434767]
- External Links
- KEGG Drug
- D07840
- KEGG Compound
- C01023
- ChemSpider
- 388489
- 1549540
- ChEBI
- 38291
- ChEMBL
- CHEMBL1950576
- ZINC
- ZINC000008216695
- PDBe Ligand
- 71R
- Wikipedia
- Dihydrostreptomycin
- PDB Entries
- 5lpa
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 16.0 mg/mL ALOGPS logP -3 ALOGPS logP -7.3 ChemAxon logS -1.6 ALOGPS pKa (Strongest Acidic) 12.11 ChemAxon pKa (Strongest Basic) 11.31 ChemAxon Physiological Charge 3 ChemAxon Hydrogen Acceptor Count 19 ChemAxon Hydrogen Donor Count 15 ChemAxon Polar Surface Area 334.59 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 150.45 m3·mol-1 ChemAxon Polarizability 56.66 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created on February 26, 2016 17:29 / Updated on February 21, 2021 18:53